- Syngene International has extended its strategic collaboration with Bristol Myers Squibb through 2035, expanding integrated services across discovery, development, manufacturing, and clinical stages.
- The agreement builds on a partnership dating back to 1998 and supports seamless progression from research to commercialization.
Syngene International has announced the extension of its long-standing strategic collaboration with Bristol Myers Squibb through 2035. The expanded agreement broadens the scope of integrated services across the drug development lifecycle, including discovery, translational sciences, pharmaceutical development, manufacturing, clinical trials, and data and information technology services.
The collaboration aims to enable a seamless transition from research to commercialization by integrating chemistry, biology, drug metabolism and pharmacokinetics, and manufacturing capabilities. Syngene said the expansion represents the next phase of growth in the partnership and reinforces its role as a strategic partner delivering end-to-end scientific and manufacturing solutions across the CDMO and contract manufacturing spectrum.
The relationship between the two companies began in 1998 and led to the establishment of the Biocon Bristol Myers Squibb Research and Development Center (BBRC), Syngene’s first dedicated R&D center, which was fully commissioned in 2009. Over time, BBRC has evolved into a major strategic R&D site for Bristol Myers Squibb, supporting integrated capabilities from target identification and lead discovery through pharmaceutical development and clinical biomarkers.
Today, the center houses around 700 Syngene scientists working as an extension of Bristol Myers Squibb’s global research organization. It contributes to discovery, preclinical development, and patent filings across therapeutic areas including cardiovascular disease, fibrosis, immunology, and oncology, and has supported the progression of novel compounds from early discovery to first-in-human studies.
“The agreement to extend this partnership through 2035 enables us to plan together for the future in terms of building new capabilities and infrastructure with a decade long horizon.”
Peter Bains, Managing Director and CEO of Syngene International
